Haemostasis is the arrest of bleeding from a broken blood vessel i.e the stopping of hemorrhage. Profuse external bleeding is a leading cause of death from traumatic injuries in civilian scenario.

AXIOSTAT^TM belongs to an advanced class of wound dressings that stops traumatic external; bleeding within few minutes of application by providing an active mechanical barrier to the wound site.

AXIOSTAT^TMalso stops moderate to severe bleeding due to:

      • Cuts 
      • Abrasions
      • Lacerations  
      • Venous/ Arterial ruptures
      • Vascular access site devices 

 

i-Nurture is the parent body of ToonSkool. ToonSkool was incorporated in the year 2004 and is headquartered at Bangalore. Promoters understood the need of a long term Animation course to bridge the skill gap between the studio’s expectation and students’ skills and became the first company in India to launch a 3-year degree course in Animation. Over the past 4 years, company has created good brand value among students and animation studios. Mr. Ashwin Ajila is Founder & Managing Director of ToonSkool Private Limited. He is a Charted Accountant, Articled and qualified with KPMG, UK.

Toonskool delivers high quality animation education through tie-ups with reputed Universities and Colleges, currently offering a 3 year BSc. course in Animation across India in reputed colleges like St. Xaviers Kolkatta, Fergusson Pune, Thakur Mumbai, NITTE & PESSE Bangalore etc. In the next 2 years, company expects to triple its network of universities and colleges.

Company plans to expand its service offerings and wants to launch several new career / industry oriented courses in upcoming technologies. Company has also started International operations recently with the launch of courses in Turkey and is planning to launch similar courses in Vietnam, Thailand and China.

GVFL’s funding of INR 110 million will be utilized towards launch of new courses and expansion to new geographies.

GVFL invests in Sebacic India Limited,incorporated in Gujarat,for setting up a greenfield plant to manufacture Sebascic acid and other byproducts, Sebacic acid is an essential input for manufacture of eco friendly plastic.

Aura Herbal Wear, engaged in the business of manufacturing, and marketing of Herbal wear textile products to the International and Indian market, has been promoted by the husband and wife duo Mr. Arun Baid and Ms. Sonal Baid.

Aura is the first company in the country to use clean technology for dyeing organic cotton and stitching garments. It utilizes a process that uniquely combines conventional dyeing machinery with natural dyeing ingredients. Herbal dyeing is a natural dye method that uses medicinally rich herbs for imparting color on cloths. Unlike conventional or low-impact dyeing processes, no chemicals or heavy metals such as chrome, copper, or tin are used in the herbal dyeing process

In conventional dyeing around 8,000 chemicals are used to dye the fabric, many of these cause irreversible damage to people and the environment. The bleaching, dyeing, sizing and finishing of textile results in release of large quantities of effluent, often contain highly toxic heavy metals that pollute the soil, water and damage aquatic life. This causes skin related problems, respiratory diseases, cancer etc.

Aura plans to utilize the GVFL finance towards setting up of a 10,000-m/day capacity plant in NIDC, Narol Ahmedabad. The company also plans to undertake distribution and market development activities throughout world. GVFL is providing early stage funding of INR 24 million to aide the company’s expansion. There is immense potential and continuous growth for this innovative venture in the fast growing organically dyed textile markets

Aura uses a patented natural dye process that allows them to use the dye effluent to irrigate agriculture and the waste to be used as fertilizer. Aura Herbal Wear is revolutionizing the organic apparel market by using biotechnology for making natural and eco-friendly dyeing on a commercial scale. Organic dyes are manufactured by fermentation of herbs in a controlled environment.

GVFL is investing INR 35 million from Gujarat IT Fund in Pegasus Semiconductor Private Limited. Pegasus Semiconductor provides energy efficient and low cost lighting solutions using LEDs (Light Emitting Diode) and Solar technologies. Pegasus is the leading company to successfully break out of the limited niche areas of solar energy and to bring it to the retail market.

Products of Pegasus Semiconductor includes 220V LED Street Light System, LED based Solar Home Lighting System and Street Lighting System. The products make use of LEDs in place of conventional CFL lamps. This helps consumer to save half of the energy in comparison to CFLs. Products require very low maintenance and have life of over 10 years. LED has a life span of 60,000 hours as compared to 10,000 hours in case of CFL. Moreover, electronic controls and devices are made with in-house technology and are optimized for longer life.

Company is setting up assembly for white LEDs and would soon start manufacturing High brightness white LED. This would be first LED manufacturing plant in India.

Pegasus Semiconductor is promoted by Dr. Sudhindra Tatti. He is B.Tech. from IIT Kharagpur & PhD in Electronics Material from University of Texas, Austin, USA. He has over 18 years experience in the semiconductor industry and is a recognized expert in areas of fault diagnostics and yield enhancement. He has worked for Motorola Semiconductor, Amberwave Systems and Semiconductor Foundries in Thailand and Singapore. The other promoter Mr. Akshat Khare is B. Tech & M.Tech from IIT Bombay , PGDM from IIM Ahmedabad and CFA. He has 2 years of entrepreneurial experience.

Amrita Therapeutics has entered into an agreement for seed funding from GVFL. This is third investment from Biotech Fund of GVFL in Ahmedabad based Amrita Therapeutics, a company promoted by Dr. Ananda Chakrabarty and Mrs. Susan Finston. Amrita is venturing into R&D for the development of novel therapies for cervical cancer, HIV-AIDs, malaria, tuberculosis etc. by designing bacterial products to defend the human body against more than one disease. Cervical cancer is one of the most common cancers among women, and is diagnosed in 4.5 lac women annually with 80% of cases in developing world resulting in about 2.7 lac fatalities each year. Amrita is the first Biotechnology Company to focus explicitly on multiple disease targeting, or MDT, drug development. Amrita’s new therapies will be characterized by fewer side effects, less likelihood of drug resistance, and will come to market at costs substantially below industry average.

Amrita Therapeutics plans to utilize the GVFL funds towards carrying out preclinical and clinical trials on the drug candidate. Eventually it would set up a Drug Development Centre in Gujarat. Amrita is being incubated at the incubator started at PERD Centre by the joint initiative of GVFL and GSBTM.

Dr. Chakrabarty is a distinguished professor in University of Illionois Medical School, Chicago and has over 30 years of experience in R&D. He has received many notable awards for his contributions to biotechnology, including the most recently awarded ‘Padmashree in 2007. Dr. Chakrabarty has 5 patents to his credit and is the first person to have a patent on living organisms which was granted by the Supreme Court of United States. He has pioneered the research of bacterial protein products useful in the body’s defense against serious illnesses and will use the knowledge exclusively for Amrita’s benefit. According to Dr Chakrabarty the resulting drugs work via multiple pathways or targets and, therefore, are likely to have a better chance of affecting the complex equilibrium of whole cellular networks than drugs that act on a single target.

GVFL has invested 110 million INR in Sahajanand Laser Technology Limited from its newly launched SME Technology Venture Fund.

GVFL has raised 60 crores for its SME Technology Venture Fund..The entire corpus of 250 crores would be raised by 2009-10.From this initial amount of SME Fund GVFL will explore new investment opportunities in IT,Biotechnology,Nanotechnogy and other sectors which are eligible for exemption under 10(23FB) of IT Act.The fund would be invested in six to eight projects within a period of 1 year with approximate investment amount ranging from 5-15 crores per project.

GVFL shall invest 25 million(INR) in Century Pharmaceuticals Limited The company is promoted by Mr Janak Sheth, a graduate from IIT Delhi .He is engaged in the business of manufacturing Active Pharmaceutical since 1982 in Vadodara.

Century Pharmaceuticals has entered into a license and development agreement with Target-In Limited , Israel for commercialization of the apoptosis based technology. Present treatments for allergy and asthma are not very efficient and safe. Effectiveness levels vary greatly but essentially offer less than maximum relief. Usually Severe asthma is treated with steroids, which cause major side effects.

This Technology
- Would provide allergy and asthma patients effective treatment that could last for three months.
- Would provide the treatment with no side effects.
- Would provide the treatment, which should be effective against a wide array of allergies.
- Would be cost effective

Market:
- Allergy is one of the most widespread diseases of the modern world. More than 25% of the population in
   industrialized countries suffers from allergies.
- The top twelve pharmaceutical products used to treat allergy and asthma by value had combined global
   sales of US$ 15.7 billion in 2005. Six brands had sales in excess of US$ 1 billion.
- Due to Urbanization and Environmental pollution India is expected to become Asthma capital
   10-20 million patients by 2020.

Century has been awarded Gold medal by IC2 Institute, USA and FICCI / Lockheed Martin during their recent survey (2007) of top ten emerging technologies in India.

Target-In CEO Dr. Shai Yarkoni and Council General of Israel Daniel Zonshine were present at the inauguration on December 29,2007 of the new laboratory in Halol, which is equipped to carry out high end R&D work

GVFL had invested Rs. 3.22 crores in Neilsoft, in April 2000 through its Gujarat Venture Capital Fund – 1995 (GVCF – 1995). – a fund for small and medium start – up/ early stage technology companies.

When GVFL invested in Neilsoft, “Engineering Design Services – CAD/CAM/CAE space,” was an emerging, innovative, niche area. Neilsoft, which in year 2000 was a small start-up, is today a Global Engineering Technology Services provider with 700 employees.

GVFL has nurtured Neilsoft for past 7 years.

Neilsoft caters to the Engineering Design Services – CAD/CAM/CAE space in the building systems, industrial machinery, automotive, marine and software verticals across the world. The Company is slated to reach Rs. 100 crores turnover in FY 2007 – 08.

Trident Capital, a US based Venture Fund & few HNI’s have acquired GVFL’s stake in Neilsoft.

Product                          In – house Application Software enabled Laser Machines for diamond
                                      processing & other industries
Location                        Gandhinagar, Gujarat
Year of Investment       2007
Amount sanctioned       INR 40 million

Uniqueness of Product/Technology:
• It has developed a complete range of application software enabled laser systems for diamond processing.
• Promoter has received/applied for several patents for his laser systems.

Details of GVFL’s investment:
Sahajanand Laser Technology Limited (SLTL), is promoted by a young technocrat, Mr. Arvind Patel.It is an ISO 9001:2000 certified company offering solutions for a wide range of application software enabled laser machines like semiconductor laser cutting system, eye ball tracking laser eye surgery machine, hallmark diode laser diamond sawing system, Akshar fiber pro laser marking system, semiconductor laser diamond multi – bruiting system and many more.

Mr. Arvind Patel has received many national awards, including the award from the Ministry of Communication & Information Technology, Dept. of Scientific and Industrial Research and Technology Development Board (Dept. of Science & Technology).

The Company plans to scale up its operations by expansion of its manufacturing facility for application software enabled laser systems.

GVFL has recently invested 80 lakhs in Rapid Radio Solutions Private Limited, Ahmedabad Rapid Radio Solution Pvt. Ltd. It is a technology start up spun up from Nirma Lab incubator programme. Investment has been made from Gujarat IT fund.
It is also GVFL’s first start up from an academic incubator programme.

Rapid Radio Solutions develops hardware products & solutions in the RFID (Radio Frequency Identification) space. It has developed various products like Proximity Reader, Midrange Reader, Long range Reader, Gate Antenna, Evaluation Kit that are customizable to customer requirements working on 13.56 MHz High Frequency range.

RFID is an auto identification technology, which is used for tracking items with a tag on it, which sends data to readers through radio waves. These tags makes the item to speak about its identity, activity, location and data stored inside through readers and finally to the application software to make the information useful.

RapidRadio is currently developing solutions for Access Control, Vehicle Identification, Campus Management and Healthcare Identification.

The Company also plans to develop products for the UHF (Ultra-High Frequency) range. Besides this, the Company will also offer RFID Transponders (Inlays, Labels & Contactless Cards) and Pad & Customs Antennas.

Mr. Dhaval Kotecha is the Promoter of RapidRadio. The Company was spun off from "RFID project" which was incubated at NirmaLabs, a Technology Business Incubator, located at Nirma University Campus, Ahmedabad.